Global Albumin Market is set to grow at a CAGR of 6% by 2026 – Growing Demand for Albumin in R&D Activities and Clinical Trials

Albumin is the most abundant circulating protein in plasma, accounting for more than half of the human plasma protein. Albumin has been globally studied as a protein carrier for drug delivery. They are used in multiple applications such as oncology, diabetes, hepatitis C, hypovolemia and rheumatoid arthritis.

Rising Demand for Albumin in Research & Development and Clinical Trials Drives the Global Albumin Market

Albumin-based therapeutic agents are widely used for treating and diagnosing malignant, inflammatory, metabolic, and viral diseases. Considering the commercial success of products which use albumin as a drug carrier and the ongoing clinical trials albumin is attracting the global interest of researchers, pharmaceutical and biotechnological companies.

Albumin-Based Nanoparticles Offers A Promising Drug Delivery System for Cancer Treatment

Albumin is a versatile biomaterial for the synthesis of nanoparticles. The efficiency of the albumin-based delivery resides in its ability to enhance tumor targeting and accumulation. Thus, albumin can bind to special receptors overexpressed on cancer cells and enhance nanoparticle binding and internalization.

Adoption of Recombinant Albumin over Serum-based Albumin for Drug Delivery

As regulatory guidelines have driven the need for animal-free options, there has been a decline in the application of serum-derived albumin. With the availability of recombinant albumin, historical risks associated with human serum albumin have been reduced. It also provides a relatively simple solution to traditional formulation strategies and provides a cost-effective and a single solution for several stability issues.

Role of Human Serum Albumin in Covid-19 Patients Boosts the Growth of Albumin Market

Albumin downregulates the expression of the ACE2 receptors and has been shown to improve the ratio of arterial partial pressure of oxygen/fraction of inspired oxygen in patients with acute respiratory distress syndrome as soon as 24 hours after treatment and with an effect which persists for seven days. Moreover, researchers who have studied the clinical characteristics of Covid-19 patients have reported that low serum albumin on presentation in COVID-19 infection is associated with a higher cases of serious outcomes like kidney injury, cardiac injury, and higher mortality, among others.

Upcoming Market Challenges: Albumin Market

The stringent government regulations, limited reimbursement, increasing shift towards serum-free solutions, and side effects associated with the use of albumin are the major factors restraining the growth of the global albumin market.

North America Holds the Largest Share but Asia-Pacific is Poised to Witness A Healthy Growth in Albumin Market

North America holds the highest market share of the albumin market. This can be mainly attributed to an increasing demand for albumin-based R&D activities, the presence of advanced and robust healthcare infrastructure, rising demand for albumin in various non-therapeutics applications and the presence of established market players in this region.

Competitive Landscape Analysis: Albumin Market

The global albumin market is marked by the presence of established market players such as Baxter International Inc. , China Biologic Products, Inc , Grifols , Apotex Inc. , and InVitria, Inc. , among others.

Companies are Adopting Reliable Growth Strategies to Increase their Market Share in the Global Albumin Market

All leading players operating in the global albumin market are adopting both organic and inorganic growth strategies such as collaborations, acquisitions, and expansions to garner a higher market share. For instance,

• In April 2022, Apotex Corp. announced the release of its Paclitaxel protein-bound particles for injection, a generic version of Abraxane in the USA.
• In January 2022, Bio Products Laboratory (BPL), announced that the National Medical Products Administration (NMPA) for China has granted BPL a license to market ALBUMINEX? 25% product to China.

Get Detailed Insights on Albumin Market with a Sample Report PDF @ https://meditechinsights.com/global-albumin-market/

#albumin #drugdelivery #drugdevelopment #recombinantalbumin?#nanoparticles #clinicaltrials #immunoglobulin #plasma #therapeutic #drugdiscovery #pharmaceutical #proteins #oncology #diabetes #hepatitisc #hypovolemia #rheumatoidarthritis #malignantdisease #inflammatoryboweldisease #inflammatory #metabolicdisease #viraldiseases #drugcarrier #biotechnology #healthcare #medicalcare #cancer #cancercells #cancerresearch #cancertreatment #respiratory #covid19 #covid19pandemic #kidneyinjury #cardiacinjury #marketresearch #researchreport